BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

710 related articles for article (PubMed ID: 35015982)

  • 1. Claims-based Prevalence of Disease Progression among Patients with Fibrosing Interstitial Lung Disease Other than Idiopathic Pulmonary Fibrosis in the United States.
    Singer D; Bengtson LGS; Conoscenti CS; Laouri M; Shetty SS; Anderson AJ; Brown KK
    Ann Am Thorac Soc; 2022 Jul; 19(7):1112-1121. PubMed ID: 35015982
    [No Abstract]   [Full Text] [Related]  

  • 2. Prevalence and Incidence of Chronic Fibrosing Interstitial Lung Diseases with a Progressive Phenotype in the United States Estimated in a Large Claims Database Analysis.
    Olson AL; Patnaik P; Hartmann N; Bohn RL; Garry EM; Wallace L
    Adv Ther; 2021 Jul; 38(7):4100-4114. PubMed ID: 34156606
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Healthcare Resources Utilization and Costs of Patients with Non-IPF Progressive Fibrosing Interstitial Lung Disease Based on Insurance Claims in the USA.
    Olson AL; Maher TM; Acciai V; Mounir B; Quaresma M; Zouad-Lejour L; Wells CD; De Loureiro L
    Adv Ther; 2020 Jul; 37(7):3292-3298. PubMed ID: 32451950
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Healthcare Resource Utilization and Related Costs in Chronic Fibrosing Interstitial Lung Diseases with a Progressive Phenotype: A US Claims Database Analysis.
    Olson AL; Hartmann N; Patnaik P; Garry EM; Bohn RL; Singer D; Baldwin M; Wallace L
    Adv Ther; 2022 Apr; 39(4):1794-1809. PubMed ID: 35199282
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Care patterns of patients with chronic fibrosing interstitial lung disease (ILD) with a progressive phenotype.
    Nili M; Singer D; Hanna M
    BMC Pulm Med; 2022 Apr; 22(1):153. PubMed ID: 35459138
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Burden of illness in progressive fibrosing interstitial lung disease.
    Singer D; Bengtson LGS; Conoscenti CS; Anderson AJ; Brekke L; Shetty SS; Brown KK
    J Manag Care Spec Pharm; 2022 Aug; 28(8):871-880. PubMed ID: 35876293
    [No Abstract]   [Full Text] [Related]  

  • 7. Nintedanib: A Review in Fibrotic Interstitial Lung Diseases.
    Lamb YN
    Drugs; 2021 Apr; 81(5):575-586. PubMed ID: 33765296
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Progressive fibrosing interstitial lung diseases: current practice in diagnosis and management.
    Wijsenbeek M; Kreuter M; Olson A; Fischer A; Bendstrup E; Wells CD; Denton CP; Mounir B; Zouad-Lejour L; Quaresma M; Cottin V
    Curr Med Res Opin; 2019 Nov; 35(11):2015-2024. PubMed ID: 31328965
    [No Abstract]   [Full Text] [Related]  

  • 9. Health care costs and utilization of progressive fibrosing lung disease by underlying interstitial lung disease type.
    Nili M; Steffens A; Anderson A; Brekke L; Grace Johnson M; Veeranki P; Olson AL
    J Manag Care Spec Pharm; 2024 Feb; 30(2):163-174. PubMed ID: 38308627
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Nationwide epidemiologic study for fibrosing interstitial lung disease (F-ILD) in South Korea: a population-based study.
    Joung KI; Park H; Park S; Shin JY; Kim YH
    BMC Pulm Med; 2023 Mar; 23(1):98. PubMed ID: 36949407
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical Characteristics and Disease Course of Fibrosing Interstitial Lung Disease Patients in a Real-World Setting.
    Kilpeläinen M; Hirvonen T; Perkonoja K; Hirsjärvi S
    Medicina (Kaunas); 2023 Jan; 59(2):. PubMed ID: 36837481
    [No Abstract]   [Full Text] [Related]  

  • 12. Possible value of antifibrotic drugs in patients with progressive fibrosing non-IPF interstitial lung diseases.
    Torrisi SE; Kahn N; Wälscher J; Sarmand N; Polke M; Lars K; Eichinger M; Heussel CP; Palmucci S; Sambataro FM; Sambataro G; Sambataro D; Vancheri C; Kreuter M
    BMC Pulm Med; 2019 Nov; 19(1):213. PubMed ID: 31718637
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Computed Tomography Honeycombing Identifies a Progressive Fibrotic Phenotype with Increased Mortality across Diverse Interstitial Lung Diseases.
    Adegunsoye A; Oldham JM; Bellam SK; Montner S; Churpek MM; Noth I; Vij R; Strek ME; Chung JH
    Ann Am Thorac Soc; 2019 May; 16(5):580-588. PubMed ID: 30653927
    [No Abstract]   [Full Text] [Related]  

  • 14. Nintedanib in patients with progressive fibrosing interstitial lung diseases-subgroup analyses by interstitial lung disease diagnosis in the INBUILD trial: a randomised, double-blind, placebo-controlled, parallel-group trial.
    Wells AU; Flaherty KR; Brown KK; Inoue Y; Devaraj A; Richeldi L; Moua T; Crestani B; Wuyts WA; Stowasser S; Quaresma M; Goeldner RG; Schlenker-Herceg R; Kolb M;
    Lancet Respir Med; 2020 May; 8(5):453-460. PubMed ID: 32145830
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prevalence and characteristics of progressive fibrosing interstitial lung disease in a prospective registry.
    Hambly N; Farooqi MM; Dvorkin-Gheva A; Donohoe K; Garlick K; Scallan C; Chong SG; MacIsaac S; Assayag D; Johannson KA; Fell CD; Marcoux V; Manganas H; Morisset J; Comes A; Fisher JH; Shapera S; Gershon AS; To T; Wong AW; Sadatsafavi M; Wilcox PG; Halayko AJ; Khalil N; Cox G; Richeldi L; Ryerson CJ; Kolb M
    Eur Respir J; 2022 Oct; 60(4):. PubMed ID: 35273032
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Exposure-safety analyses of nintedanib in patients with chronic fibrosing interstitial lung disease.
    Schmid U; Weber B; Sarr C; Freiwald M
    BMC Pulm Med; 2021 Jul; 21(1):244. PubMed ID: 34289823
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Epidemiology and real-life experience in progressive pulmonary fibrosis.
    Valenzuela C; Cottin V
    Curr Opin Pulm Med; 2022 Sep; 28(5):407-413. PubMed ID: 35938201
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Characterizing Health Outcomes in Idiopathic Pulmonary Fibrosis using US Health Claims Data.
    Mortimer KM; Bartels DB; Hartmann N; Capapey J; Yang J; Gately R; Enger C
    Respiration; 2020; 99(2):108-118. PubMed ID: 31982886
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Association between Pepsin in Bronchoalveolar Lavage Fluid and Prognosis of Chronic Fibrosing Interstitial Lung Disease.
    Kim Y; Lee YJ; Cho YJ; Yoon HI; Lee JH; Lee CT; Park JS
    Tohoku J Exp Med; 2018 Nov; 246(3):147-153. PubMed ID: 30405002
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Progressive fibrosing interstitial lung diseases: A new concept and indication of nintedanib.
    Makino S
    Mod Rheumatol; 2021 Jan; 31(1):13-19. PubMed ID: 32964766
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 36.